Andere talen Precision BioSciences, Inc.

Aandelen

DTIL

US74019P2074

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
9,74 ^USD	-9,14%		-31,02%	-11,05%

16/04	Transcript : Precision BioSciences, Inc. - Special Call
16/04	Precision BioSciences, Inc. kondigt teruggave van programma's en beëindiging van samenwerking met Prevail Therapeutics aan	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration	16/04
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics	16/04
Precision BioSciences, Inc. Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics	16/04
Precision BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Precision BioSciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/03
Precision BioSciences: Q4 Earnings Snapshot	27/03
Earnings Flash (DTIL) PRECISION BIOSCIENCES Posts Q4 Revenue $7M	27/03
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update	27/03
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024	20/03
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy	19/03
IECURE SECURES APPROVAL FROM U.K. MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY TO EXPAND THE OTC-HOPE STUDY OF ECUR-506	07/03
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency	06/03
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency	06/03
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants	04/03
Precision BioSciences Launches $40 Million Public Offering; Shares Slump	01/03
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants	01/03
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants	29/02
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences	20/02
Precision BioSciences, Inc. Announces Non-Exclusive Patent License Agreement with Caribou Biosciences	20/02
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness	14/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Precision BioSciences, Inc.

Aandelen

DTIL

US74019P2074

Andere talen

Filters